je.st
news
MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research
2016-01-16 23:09:46| Biotech - Topix.net
The brokerage presently has a $1.00 target price on the biopharmaceutical company's stock. Zacks Investment Research 's price objective indicates a potential upside of 7.71% from the company's current price.
Tags: buy
research
investment
upgraded
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||